Comorbid alcohol use disorder and posttraumatic stress disorder: A proof‐of‐concept randomized placebo‐controlled trial of buprenorphine and naltrexone combination treatment
Abstract
Effective pharmacologic treatments for comorbid alcohol use disorder (AUD) and posttraumatic stress disorder (PTSD) are lacking. Kappa (κ) opioid receptor antagonists may address this unmet need. Buprenorphine is a κ‐opioid antagonist and a partial agonist of mu (μ) opioid receptors. Whereas naltrexone blocks all μ‐mediated effects combining it with buprenorphine yields a pharmacologic net effect of opioid receptor antagonism. Because no κ‐opioid receptor antagonist it available for clinical use, we tested this combination in a proof‐of‐concept study.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 30, 2023
- Source ID
- 10.1111/acer.15155
Entities
People
- Ismene L. Petrakis
- Lori L Davis
- Nathan Vandergrift
- Patricia D. Pilkinton
- Seth D. Norrholm
- Shawn Hirsch
- Thomas R Kosten
- Tracy Nolen
Organizations
- Baylor College of Medicine
- Michael E. DeBakey Veterans Affairs Medical Center in Houston
- RTI International
- United States Air Force Academy
- University of Alabama at Birmingham
- VA Connecticut Healthcare System
- Veterans Health Administration
- Wayne State University
- Yale University